Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | CA6 | P23280 | 3/20 | 0.50 |
| ▸ | CA5A | P35218 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.50 |
| ▸ | F13A1 | P00488 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | THPO | P40225 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12638433 | 0.93 | CA12 (0.48) | CA12CA2CA4CA6CA5A | |
| SCHEMBL13100404 | 0.88 | — | — | |
| SCHEMBL13602599 | 0.88 | CA12 (0.43) | CA12CA2CA4CA6CA5A | |
| SCHEMBL8863209 | 0.84 | CA12 (0.48) | CA12CA2CA4CA6CA5A | |
| SCHEMBL21799794 | 0.84 | CA12 (0.48) | CA12CA2CA4CA6CA5A | |
| SCHEMBL11552695 | 0.83 | ANPEP (0.49) | TSHR | |
| SCHEMBL8508565 | 0.83 | ANPEP (0.49) | TSHR | |
| SCHEMBL11557774 | 0.83 | ANPEP (0.49) | TSHR | |
| SCHEMBL11556054 | 0.83 | ANPEP (0.49) | TSHR | |
| SCHEMBL21799727 | 0.83 | CA12 (0.46) | CA12CA2CA4CA6CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106132402-A | Pharmaceutical product for the prevention and treatment of progressive myopia | 伊万·德米崔伊维奇·扎哈洛夫 | 2016-11-16 | — | — | CN | claimed |
| US-20220365090-A1 | PEPTOID, AND ITS PREPARATION METHOD AND USE | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2022-11-17 | — | — | US | disclosed |
| CN-106132402-A | Pharmaceutical product for the prevention and treatment of progressive myopia | 伊万·德米崔伊维奇·扎哈洛夫 | 2016-11-16 | — | — | CN | disclosed |
| US-20120015901-A1 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015901-A1 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS | BECN1, SQSTM1, ATG7 | CA12 3941/4885CA2 3964/4885CA4 4066/4885 |
| US-20220365090-A1 | PEPTOID, AND ITS PREPARATION METHOD AND USE | EPCAM, EPDR1, EPB41 | CA12 267/4885CA2 695/4885CA4 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.